| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD) |
| Completed | 3 | 300 | Europe, Canada, US, RoW | 89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX) | Telix Pharmaceuticals (Innovations) Pty Limited | Clear Cell Renal Cell Carcinoma | 10/22 | 11/22 | | |
2008-004548-35: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER |
|
|
| Ongoing | 2 | 9 | Europe | cG250, cG250, | Radboud university nijmegen medical centre | Patients with metastatic clear cell renal cell carcinoma | | | | |
OPALESCENCE, NCT04758780: Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients |
|
|
| Recruiting | 2 | 12 | Europe | 89Zr-TLX250 PET/CT | Institut Cancerologie de l'Ouest, Telix Pharmaceutical, SIRIC ILIAD | Triple Negative Breast Cancer | 03/24 | 06/24 | | |
| Recruiting | 2 | 41 | US | 177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans | Memorial Sloan Kettering Cancer Center | Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma | 03/25 | 03/25 | | |
NCT05563272: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors |
|
|
| Recruiting | 2 | 100 | US | 89Zr-DFO-girentuximab | Telix International Pty Ltd | Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 12 | RoW | 89Zr-Girentuximab | Telix International Pty Ltd | Urothelial Carcinoma, Bladder Cancer | 02/22 | 05/22 | | |
NCT05663710: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC |
|
|
| Active, not recruiting | 1/2 | 100 | US | 177Lu girentuximab, Nivolumab, BMS-936558, Opdivo, Cabozantinib, XL-184, XL184, ArabinoFuranosylGuanine [18F]F-AraG | M.D. Anderson Cancer Center, Telix Pharmaceuticals Limited | Advanced Cancer, Clear Cell Renal Cell Carcinoma | 10/25 | 10/27 | | |
ACTRN12621000411842: A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) Position Emission Tomography (PET) in Urothelial Cancer Patients |
|
|
| Not yet recruiting | 1 | 20 | | | South Metropolitan Health Services, Telix International Pty Ltd | Metastatic urothelial carcinoma, Bladder cancer | | | | |
NCT02497599: Intraoperative Dual-modality Imaging in Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 30 | Europe | Indium-111-DOTA-Girentuximab-IRDye800CW, Dual-labeled girentuximab, SPECT/CT, Intraoperative dual-modality imaging, Fluorescence and radioguided surgery | Radboud University Medical Center | Carcinoma, Renal Cell | 12/21 | 04/22 | | |
ZiPUP, NCT05046665: Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients |
|
|
| Completed | 1 | 11 | RoW | 89Zr-Girentuximab | South Metropolitan Health Service, Telix Pharmaceuticals (Innovations) Pty Limited | Urothelial Carcinoma | 08/22 | 08/22 | | |
PERTINENCE, NCT04897763: Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) |
|
|
| Completed | 1 | 6 | Europe | 89Zr-TLX250 PET/CT | Institut Cancerologie de l'Ouest, ATONCO | Bladder Cancer | 08/22 | 09/22 | | |
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma |
|
|
| Completed | 1 | 10 | RoW | 89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx | Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd. | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | 11/23 | 11/23 | | |
NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | 89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany | Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma | 12/24 | 12/26 | | |
NCT01582204: Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 17 | US | 124IcG250 | Memorial Sloan Kettering Cancer Center, Telix Pharmaceutical | Renal Cancer | 04/25 | 04/25 | | |